Lazabemide
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C8H10ClN3O |
Molar mass | 199.64 g/mol |
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References[edit]
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |